Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DexCom, Inc. (DXCM) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance

DexCom, Inc.Trade
Vanguard High Dividend Yield ETFTrade

Price performance (Past 24H)

Key statistics

DexCom, Inc. vs Vanguard High Dividend Yield ETF — how do they compare? DexCom, Inc. trades at $90.14 (market cap $33.79B), while Vanguard High Dividend Yield ETF trades at $166.5. Which is the better fit depends on your goals.

DXCMVYM
Market Cap
$33.79B
Sector
Health
52-Week High
$89.53$166.14
52-Week Low
$54.84$136.63
Enterprise Value
$33.24B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DexCom, Inc.

DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.

The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.

Vanguard High Dividend Yield ETF

VYM trades at $166.36, up 0.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF focuses on high dividend yield stocks, offering income appeal, though key valuation ratios like P/E and P/B are not available. Recent news highlights institutional position adjustments and discussions on its role in retirement income portfolios.

Outlook is mixed: technical indicators suggest near-term caution due to overbought conditions, while the dividend strategy supports long-term income. Risks include market volatility and yield compression. Analyst sentiment is generally positive for income-focused investors, but monitor for pullbacks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM

About Vanguard High Dividend Yield ETF

The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.

Read more on VYM